Filtern
Volltext vorhanden
- ja (22)
Gehört zur Bibliographie
- ja (22)
Dokumenttyp
Sprache
- Englisch (22)
Schlagworte
- adrenocortical carcinoma (3)
- hypercortisolism (3)
- miRNA (3)
- CYP2W1 (2)
- Cushing’s syndrome (2)
- FGF-pathway (2)
- FGFR (2)
- adrenal tumours (2)
- adrenocortical cancer (2)
- adrenocortical tumors (2)
- biomarker (2)
- cortisol (2)
- mitotane (2)
- mortality (2)
- neuroendocrine tumor (2)
- osteoporosis (2)
- prognosis (2)
- vitamin D (2)
- ACC (1)
- ACTH (1)
- BIRC7 (1)
- CTNNB1 (1)
- CXCR4 (1)
- CXCR7 (1)
- CYP2B6 (1)
- Cushing’s disease (1)
- EMT (1)
- FGFR-inhibitors (1)
- LCNEC (1)
- MEN1 (1)
- NR3C1 (1)
- RNA Expression (1)
- RNAScope (1)
- SNP (1)
- USP8 (1)
- adjuvant therapy (1)
- adjuvant treatment (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenal tumor (1)
- adrenocortical adenoma (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical development (1)
- adrenocortical tissues (1)
- adrenocortical tumor (1)
- age (1)
- autonomous cortisol secretion (1)
- bioinformatic clustering (1)
- biomarker prediction (1)
- blood pressure (1)
- bone (1)
- bone metabolism (1)
- cancer (1)
- cancer treatment (1)
- carcinomas (1)
- cardiovascular diseases (1)
- cardiovascular events (1)
- cardiovascular risk factors (1)
- caspase-3 (1)
- chemokine receptor (1)
- chronotype (1)
- circadian rhythms (1)
- cortisol-producing adenoma (1)
- dexamethasone suppression test (1)
- drug therapy (1)
- efficacy (1)
- endocrine cancer (1)
- epidemiology (1)
- epithelial markers (1)
- genetic analysis (1)
- glucocorticoid excess (1)
- hormones (1)
- immune response (1)
- immunity (1)
- immunohistochemistry techniques (1)
- immunotherapy (1)
- in silico analysis (1)
- isturisa (1)
- livin (1)
- lncRNA (1)
- lymph nodes (1)
- lymphocytes (1)
- machine learning (1)
- medical therapy (1)
- menopause (1)
- mesenchymal markers (1)
- metyrapone (1)
- miR-182-5p (1)
- miR-183 cluster (1)
- mineral bone density (1)
- morbidity (1)
- neurofibromatosis type 1 (1)
- normal adrenal glands (1)
- obesity (1)
- osilodrostat (1)
- paraganglioma (1)
- patient survival (1)
- personalised medicine (1)
- pheochromocytoma (1)
- predictive marker (1)
- prognostic marker (1)
- prognostic markers (1)
- pulmonary cancer (1)
- radiotherapy (RT) (1)
- recurrence (1)
- recurrence free survival (1)
- recurrence-free survival (1)
- serotonin (1)
- surgery (1)
- surgical oncology (1)
- surveillance (1)
- survival (1)
- t-lymphocytes (1)
- therapy (1)
- timing (1)
- tumor (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- type 2 diabetes (1)
- unsupervised clustering (1)
Institut
- Medizinische Klinik und Poliklinik I (22)
- Pathologisches Institut (7)
- Comprehensive Cancer Center Mainfranken (5)
- Klinik und Poliklinik für Nuklearmedizin (2)
- Center for Computational and Theoretical Biology (1)
- Institut für Klinische Biochemie und Pathobiochemie (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Strahlentherapie (1)
- Medizinische Klinik und Poliklinik II (1)
Background
Adrenal incidentalomas with cortisol autonomy are associated with increased cardiovascular morbidity and mortality. Specific data on the clinical and biochemical course of affected patients are lacking.
Methods
Retrospective study from a tertiary referral centre in Germany. After exclusion of overt hormone excess, malignancy and glucocorticoid medication, patients with adrenal incidentalomas were stratified according to serum cortisol after 1 mg dexamethasone: autonomous cortisol secretion (ACS), >5.0; possible ACS (PACS), 1.9-5.0; non-functioning adenomas (NFA), ≤1.8 µg/dl.
Results
A total of 260 patients were enrolled (147 women (56.5%), median follow-up 8.8 (2.0-20.8) years). At initial diagnosis, median age was 59.5 (20-82) years, and median tumour size was 27 (10-116) mm. Bilateral tumours were more prevalent in ACS (30.0%) and PACS (21.9%) than in NFA (8.1%). Over time, 40/124 (32.3%) patients had a shift of their hormonal secretion pattern (NFA to PACS/ACS, n=15/53; PACS to ACS, n=6/47; ACS to PACS, n=11/24; PACS to NFA, n=8/47). However, none of the patients developed overt Cushing’s syndrome. Sixty-one patients underwent adrenalectomy (NFA, 17.9%; PACS, 24.0%; ACS, 39.0%). When non-operated patients with NFA were compared to PACS and ACS at last follow-up, arterial hypertension (65.3% vs. 81.9% and 92.0%; p<0.05), diabetes (23.8% vs. 35.6% and 40.0%; p<0.01), and thromboembolic events (PACS: HR 3.43, 95%-CI 0.89-13.29; ACS: HR 5.96, 95%-CI 1.33-26.63; p<0.05) were significantly less frequent, along with a trend towards a higher rate of cardiovascular events in case of cortisol autonomy (PACS: HR 2.23, 95%-CI 0.94-5.32; ACS: HR 2.60, 95%-CI 0.87-7.79; p=0.1). Twenty-five (12.6%) of the non-operated patients died, with higher overall mortality in PACS (HR 2.6, 95%-CI 1.0-4.7; p=0.083) and ACS (HR 4.7, 95%-CI 1.6-13.3; p<0.005) compared to NFA. In operated patients, prevalence of arterial hypertension decreased significantly (77.0% at diagnosis to 61.7% at last follow-up; p<0.05). The prevalence of cardiovascular events and mortality did not differ significantly between operated and non-operated patients, whereas thromboembolic events were significantly less frequent in the surgical treatment group.
Conclusion
Our study confirms relevant cardiovascular morbidity in patients with adrenal incidentalomas (especially those with cortisol autonomy). These patients should therefore be monitored carefully, including adequate treatment of typical cardiovascular risk factors. Adrenalectomy was associated with a significantly decreased prevalence of hypertension. However, more than 30% of patients required reclassification according to repeated dexamethasone suppression tests. Thus, cortisol autonomy should ideally be confirmed before making any relevant treatment decision (e.g. adrenalectomy).